Payment overview · 2025
General Payments
$511.30
21 reported records · 11 companies
Healthcare provider profile · identity verified
Irina Muni, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLOOMFIELD, CT · NPI 1215958301
Verified facts
What the public records show
CMS Open Payments records show Irina Muni, MD received $511.30 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $131.65 | 25.8% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.26 | 18.2% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $59.38 | 11.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $48.65 | 9.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.00 | 9.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.23 | 5.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.42 | 4.6% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.37 | 4.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $23.33 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.43 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.58 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $511.30 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.69 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.69 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $59.38 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $59.38 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $51.02 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $48.65 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.96 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 265 | 78 |
| Lisinopril | Lisinopril | 253 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 78 |
| Lorazepam | Lorazepam | 233 | 54 |
| Simvastatin | Simvastatin | 138 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 135 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 38 |
| Losartan Potassium | Losartan Potassium | 125 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 30 |
| Omeprazole | Omeprazole | 119 | 32 |
| Ozempic | Semaglutide | 117 | 19 |
| Prednisone | Prednisone | 115 | 69 |
| Metformin Hcl Er | Metformin Hcl | 113 | 34 |
| Alprazolam | Alprazolam | 111 | 40 |
| Tramadol Hcl | Tramadol Hcl | 111 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 38 |
| Meloxicam | Meloxicam | 98 | 30 |
| Jardiance | Empagliflozin | 90 | 20 |
| Metformin Hcl | Metformin Hcl | 85 | 23 |
| Ezetimibe | Ezetimibe | 83 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 16 |
| Gabapentin | Gabapentin | 72 | 21 |
| Eliquis | Apixaban | 71 | 18 |
| Allopurinol | Allopurinol | 70 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 21 |
| Clonazepam | Clonazepam | 64 | 15 |
| Montelukast Sodium | Montelukast Sodium | 57 | 15 |
| Valsartan | Valsartan | 57 | 17 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 53 | 11 |
| Furosemide | Furosemide | 49 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 47 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 16 |
| Glimepiride | Glimepiride | 45 | 11 |
| Methocarbamol | Methocarbamol | 43 | 20 |
| Carvedilol | Carvedilol | 42 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Famotidine | Famotidine | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 12 |
| Temazepam | Temazepam | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 11 |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Torsemide | Torsemide | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 15 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Oxazepam | Oxazepam | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $511.30 · 21 records | Novo Nordisk Inc | CAPVAXIVE, FREESTYLE LIBRE 3, Fluad, Flucelvax, GARDASIL 9, KRYSTEXXA, Leqembi, OPSUMIT, OTEZLA, Ozempic, REPATHA, Rybelsus, UPTRAVI, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error